Value
3.9/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 1.4 |
| Fwd P/E | 3.9 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 30.4x
- ▸PEG: 0.21
URGN · Why this verdict
Why UroGen Pharma (URGN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
UroGen's Rule of 40 score of 74 (rated elite) combined with 152% year-over-year revenue growth signals a business scaling efficiently despite ongoing cash burn. Quality breakdown | The Rule of 40 score should stay above 60 and revenue growth above 50% YoY over the next 12 months to sustain the elite growth profile. | →Stable |
| CounterThe company is still cash-burning at -78% of revenue, so the elite Rule of 40 reading depends on growth continuing to outpace burn, which biotech commercial ramps can reverse quickly. | ||
The stock has already reached its analyst price target, leaving only 2.1% upside to the take-profit level versus 7.0% downside to the stop-loss, and the engine's asymmetry gate failed at a ratio of -1.0. Engine gate (failed) | A new, higher price target or take-profit level should emerge to restore positive asymmetry over the next 12 months. | →Stable |
| CounterA stock reaching its target while still growing revenue 152% YoY may reflect thin analyst coverage rather than genuine overvaluation. | ||
The stock is overbought with an RSI of 90, trading near its 52-week high (4.0% away) and above its 200-day moving average, reflecting strong but potentially stretched positive momentum. Momentum breakdown | RSI should cool to below 70 while the stock holds above its 200-day moving average over the next 2 quarters, confirming healthy consolidation rather than a reversal. | →Stable |
| CounterAn RSI reading this extreme frequently precedes a sharp pullback, especially alongside the two consecutive earnings misses flagged in the bear case. | ||
The company has missed earnings estimates in 2 of the last 4 quarters with an average surprise of -7.2%, a pattern flagged directly as consecutive earnings misses. Bear case | The company should beat or meet estimates with a positive average surprise over the next 4 quarters to reverse the miss pattern. | →Stable |
| CounterThe misses were modest relative to typical swings on a pre-profitability biotech's small EPS base, so the pattern may not indicate structural deterioration. | ||
Short interest stands at 14% of float alongside modest but consistent insider selling of $792,661 over 90 days across 3 separate sales, both flagged as key risks. Key risks | Short interest should decline below 10% and insider selling should not escalate beyond the current 0.043% of market cap over the next 12 months. | →Stable |
| CounterAt only 0.043% of market cap, the insider selling is immaterial in dollar terms and may reflect routine diversification rather than a negative signal. | ||
UroGen's Rule of 40 score of 74 (rated elite) combined with 152% year-over-year revenue growth signals a business scaling efficiently despite ongoing cash burn.
→StableQuality breakdown
- Expectation
- The Rule of 40 score should stay above 60 and revenue growth above 50% YoY over the next 12 months to sustain the elite growth profile.
CounterThe company is still cash-burning at -78% of revenue, so the elite Rule of 40 reading depends on growth continuing to outpace burn, which biotech commercial ramps can reverse quickly.
The stock has already reached its analyst price target, leaving only 2.1% upside to the take-profit level versus 7.0% downside to the stop-loss, and the engine's asymmetry gate failed at a ratio of -1.0.
→StableEngine gate (failed)
- Expectation
- A new, higher price target or take-profit level should emerge to restore positive asymmetry over the next 12 months.
CounterA stock reaching its target while still growing revenue 152% YoY may reflect thin analyst coverage rather than genuine overvaluation.
The stock is overbought with an RSI of 90, trading near its 52-week high (4.0% away) and above its 200-day moving average, reflecting strong but potentially stretched positive momentum.
→StableMomentum breakdown
- Expectation
- RSI should cool to below 70 while the stock holds above its 200-day moving average over the next 2 quarters, confirming healthy consolidation rather than a reversal.
CounterAn RSI reading this extreme frequently precedes a sharp pullback, especially alongside the two consecutive earnings misses flagged in the bear case.
The company has missed earnings estimates in 2 of the last 4 quarters with an average surprise of -7.2%, a pattern flagged directly as consecutive earnings misses.
→StableBear case
- Expectation
- The company should beat or meet estimates with a positive average surprise over the next 4 quarters to reverse the miss pattern.
CounterThe misses were modest relative to typical swings on a pre-profitability biotech's small EPS base, so the pattern may not indicate structural deterioration.
Short interest stands at 14% of float alongside modest but consistent insider selling of $792,661 over 90 days across 3 separate sales, both flagged as key risks.
→StableKey risks
- Expectation
- Short interest should decline below 10% and insider selling should not escalate beyond the current 0.043% of market cap over the next 12 months.
CounterAt only 0.043% of market cap, the insider selling is immaterial in dollar terms and may reflect routine diversification rather than a negative signal.
TrendMatrix Research · core thesis
Engine thesis — one sentence
UroGen combines an elite Rule of 40 growth profile (74) with strong recent momentum, but the stock has already reached its price target with negative asymmetry, sits overbought near 52-week highs, and carries two recent earnings misses alongside elevated short interest and modest insider selling.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.3 |
| FCF quality | 0.0 |
| Moat | 7.0 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -78% of revenue
- ▸Rule of 40: 74 (elite)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 152% YoY
Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.3 |
- ▸Overbought (RSI 82)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 9.0 |
| Analyst rating | 7.9 |
| Price target | 4.6 |
- ▸LLM news sentiment: +0.80 (n=1)
- ▸Light analyst coverage (8.0) — signal dampened
Insider
5.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Modest insider selling — $792,661 (0.043% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.4 |
| quality rank | 0.0 |
| growth rank | 9.0 |
- ▸Industry growth leader
Technical
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.0 |
| support resistance | 1.2 |
| 52w position | 9.2 |
| gap | 6.0 |
Risk (lower is worse)
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.1 |
| days to cover | 0.2 |
| volatility | 0.4 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 4.8 |
| news risk | 5.5 |
- ▸High IV: 116%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/2M
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position. | News modifier -1 (HOLD_IF_HOLDING → SELL_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULT|L3:NEWS_MOD=-1Passed (5)
- MOMENTUM:7.2>=5.5
- INSIDER:OK
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.0=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.00
Upside
-15.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: MOMENTUM:7.2>=5.5. Top dim: Growth at 10.0; weakest: Catalyst at 3.2. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Growth at 10.0, Sentiment at 7.3, and Momentum at 7.2; the weakest are Catalyst at 3.2, Risk (lower is worse) at 3.4, and Value at 3.9. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Rule Of 40 Growth
Trip ifRule of 40 score falls below 40 from the current 74.
- P2Target Reached Limited Upside
Trip ifAsymmetry ratio rises above 1.5 from the current -1.0.
- P3Overbought Momentum Near High
Trip ifStock price falls below the 200-day moving average, a decline of more than 10% from the current $38.02.
- P4Earnings Miss Pattern
Trip ifEarnings surprise rises above 0% for 2 consecutive quarters.
- P5Elevated Short Interest Insider Selling
Trip ifShort interest falls below 8% of float from the current 14%.